Testing Experimental Psoriasis Drug in Healthy Subjects
Study Description
“A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis”
This is a study to evaluate pharmacokinetics (PK), safety and tolerability of ABBV-157 in healthy volunteers and in participants with chronic plaque psoriasis, and to evaluate the efficacy of ABBV-157 in the participants with psoriasis. This study consists of two substudies. Substudy 1 is a randomized, double-blind, placebo-controlled evaluation of multiple ascending oral doses of ABBV-157 in healthy adult volunteers. Substudy 2 is a randomized, double-blind, placebo-controlled study in which participants with moderate to severe chronic plaque psoriasis will be administered multiple oral doses of ABBV-157.
Location
Methods
Pharmaceutical medication involved
Patients and healthy individuals accepted
Drug - ABBV-157
ABBV-157 will be administered orally as capsule
Drug - Placebo for ABBV-157
Placebo for ABBV-157 will be administered orally as capsule
Additional Information
Official Study Title
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Subjects With Chronic Plaque Psoriasis
Clinical Trial ID
NCT03922607
ParticipAid ID
bkRlva
